

**Supplementary Table 3.** Detailed chemotherapy regimens of the enrolled patients

Patient no.	1st line		2nd line		3rd line		4th line	
	Regimen	Cycle	Regimen	Cycle	Regimen	Cycle	Regimen	Cycle
1	EP	2	-	-	-	-	-	-
2	XELOX	8	XELIRI	3	-	-	-	-
3	XELOX	8	XELIRI+simvastatin	8	FOLFOX	12	-	-
4 <sup>a)</sup>	XELOX	8	mFOLFIRI	11	IC	2	5-FU+Avastin	7
5	S1+oxaliplatin	18	FOLFIRI+simvastatin	15	FOLFOX	11	Xeloda	2
6	Pazopanib	1	RADIANT study	9	Octreotide	9	-	-
7	XELOX	9	XELIRI	8	FL	3	Regorafenib	3
8	XELOX+Avastin	11	mFOLFIRI	12	IC	3	-	-
9	XELOX+Avastin	8	FOLFIRI+simvastatin	12	IC	12	Cetuximab	4
10	FOLFIRI	1	-	-	-	-	-	-

EP, etoposide and cisplatin; XELOX, capecitabine and oxaliplatin; XELIRI, capecitabine and irinotecan; FOLFOX, fluorouracil and oxaliplatin; mFOLFIRI, fluorouracil, leucovorin and irinotecan.

<sup>a)</sup>Received additional 4 cycles of regorafenib.